Researchers have developed a gene therapy strategy to selectively manipulate Parkinson's disease-affected circuitry and attenuate the core motor symptoms of Parkinson's disease in rodent and nonhuman primate animals. The study was published in Cell .
Parkinson's disease, characterized by the loss of midbrain dopaminergic neurons, is one of the most common neurodegenerative diseases in the elderly population, affecting more than 6 million people worldwide.
Dopamine receptor D1-expressing and D2-expressing medium spiny neurons (D1-MSN and D2-MSN, respectively) constitute 90% of neurons in the striatum. Both D1-MSN and D2-MSN receive dopaminergic innervation from the substantia nigra pars compacta (SNc), yet play opposing roles in movement control.
D1-MSNs that project to the globus pallidus internal segment (GPi) and substantia nigra pars reticulata (SNr) constitute the direct pathway and promote movement. In contrast, D2-MSNs that project to the globus pallidus external segment (GPe) form the indirect pathway and mediate movement inhibition.
In Parkinson's disease, dopamine depletion causes hypoactivity of the direct pathway and hyperactivity of the indirect pathway, resulting in various motor symptoms.
Levodopa (L-Dopa)-based treatment, which helps to restore the dopamine system's function, is the mainstay therapy for Parkinson's disease. Unfortunately, almost all patients given long-term L-Dopa treatment suffer from motor complications (e.g., motor fluctuations and dyskinesia). Thus, precise, efficient and stable treatments are greatly needed.
Since the SNr receives dense projection from the D1-MSNs and no projection from the D2-MSNs, the researchers proposed that D1-MSNs could be selectively labeled by injecting highly efficient retrograde adeno-associated virus (AAV) into the SNr and then be exclusively manipulated by introducing neuronal activity-regulating elements in the retrograde AAV.
To achieve the above objectives, they developed a novel AAV capsid, AAV8R12, for efficient retrograde labeling of the D1-MSN in the striatum as well a new promoter G88P2/3/7 with strong D1-MSN activity. With a chemogenetic effector rM3Ds to match systemic administration of the activation drug, this gene therapy strategy was able to specifically activate D1-MSN and thus drive the D1-MSN-mediated direct pathway.
Typical motor symptoms such as bradykinesia, rigidity, and tremor were greatly improved in primate models with Parkinson’s disease after applying the circuit-specific approach targeting D1-MSNs. For example, bradykinesia was greatly reduced, tremor was completely eliminated, and motor skills were restored.
Unlike L-Dopa treatment which non-specifically activates the dopamine system in both the brain and peripheral organs, this new approach precisely manipulates the D1-MSN-mediated direct pathway.
In addition to its therapeutic effectiveness, this circuit-manipulating gene therapy has faster onset and longer duration compared to L-Dopa treatment. The alleviation of symptoms after a single drug administration lasts longer than 24 hours compared to a typical 6-hour therapeutic window for L-Dopa. Motor complications such as dyskinesia shown after L-Dopa treatment were absent after applying the gene therapy over an extended period (i.e., over eight months).
Besides showing potential for treating Parkinson's disease, this circuit-manipulating gene therapy paves the way for future development of targeted, circuit-based therapeutic strategies for other brain disorders.
https://www.cell.com/cell/fulltext/S0092-8674(23)01086-3
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fcircuit-specific-gene&filter=22
Circuit-specific gene therapy for treating Parkinson's disease
- 805 views
- Added
Latest News
Which of the two DNA strand…
By newseditor
Posted 16 Jun
Microglia depletion prevent…
By newseditor
Posted 16 Jun
Colorectal cancer stem cell…
By newseditor
Posted 16 Jun
Paranoia in the brain
By newseditor
Posted 16 Jun
In-vitro 3D culture of func…
By newseditor
Posted 15 Jun
Other Top Stories
Atoh1 is critical to establish the diversity of pontine nuclei neurons
Read more
Controlling the balance between genome expression and maintenance i…
Read more
Revisiting theories of consciousness
Read more
Traffic control' system for mucin and insulin secretion identified
Read more
Antipsychotic drugs work differently than believed
Read more
Protocols
Bioengineered human colon o…
By newseditor
Posted 14 Jun
Development of an efficient…
By newseditor
Posted 12 Jun
A co-culture system of macr…
By newseditor
Posted 10 Jun
Analysis of 3D pathology sa…
By newseditor
Posted 08 Jun
Long-term expandable mouse…
By newseditor
Posted 07 Jun
Publications
Pathways for macrophage upt…
By newseditor
Posted 16 Jun
Common and distinct neural…
By newseditor
Posted 16 Jun
Strand-resolved mutagenicit…
By newseditor
Posted 16 Jun
Innate-like T cells in live…
By newseditor
Posted 16 Jun
Membrane to cortex attachme…
By newseditor
Posted 16 Jun
Presentations
Myelin plasticity in the ve…
By newseditor
Posted 10 Jun
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar